FindTrial
Sign In

Effect of a drug (inj Clonidine) with Ropivacaine in a block for control of pain in breast surgery

"Comparison of analgesic effect of Clonidine as adjuvant with 0.35% concentration of Ropivacaine in USG guided thoracic Paravertebral block in modified radical Mastectomy: A prospective randomized double blind Study"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045531
Enrollment
78
Registered
2022-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: O- Medical and Surgical

Interventions

Intervention1: ropivacaine with clonidine: USG guided local injection of ropivacaine 0.35%, 19ml diluted up to 20ml in normal saline & clonidine 1mcg/kg in ipsilateral paravertibral space by 23G spin

Sponsors

Department Of Anaesthesia RNT Medical College udaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are 18-60 year of age, ASA grade I and II, Normotensives or treated Hypertensives who will undergo MRM surgery will be included in the study

Exclusion criteria

Exclusion criteria: Patient refusal,Patients with ASA III and higher,Patient having allergy to study drugs, Coagulation disorders,History of cardiovascular disease, Uncontrolled blood pressure,Pregnancy

Design outcomes

Primary

MeasureTime frame
DURATION OF ANALGESIATimepoint: up to 24 hrs after completion of surgery—

Secondary

MeasureTime frame
THE RESCUE ANALGESIC REQUIREMENTTimepoint: OVER FIRST 24 HRS POSTOPERATIVELY—

Countries

India

Contacts

Public ContactAmit kumar mittal

RNT Medical College, Udaipur

drlalitkumar@hotmail.com9414352823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026